AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2022
Jan 5, 2022
30751_dirs_2022-01-05_fe7b9036-4c93-407c-8d89-a1d5d6478532.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-01-03
Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-03 | Ordinary Shares | M | 9700 | $46.83 | Acquired | 328251 | Direct |
| 2022-01-03 | Ordinary Shares | S | 1819 | $126.72 | Disposed | 326432 | Direct |
| 2022-01-03 | Ordinary Shares | S | 1181 | $127.58 | Disposed | 325251 | Direct |
| 2022-01-03 | Ordinary Shares | S | 2651 | $128.67 | Disposed | 322600 | Direct |
| 2022-01-03 | Ordinary Shares | S | 140 | $129.34 | Disposed | 322460 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | Non-Qualified Stock Option (right to buy) | $46.83 | M | 9700 | Disposed | 2022-08-08 | Ordinary Shares (9700) | Direct |
Footnotes
F1: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $126.14 to $127.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $127.15 to $127.945. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $128.23 to $129.09. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $129.285 to $129.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F7: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.